Albany, NY -- (SBWIRE) -- 11/29/2018 -- DelveInsight has announced the addition of the "Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of AD for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Atopic Dermatitis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Atopic Dermatitis (AD) as the chronic or recurrent inflammatory skin disease, which belongs to the group of allergic disorders that includes food allergy, allergic rhinitis, and asthma. It is a chronic inflammatory skin disease and the clinical picture is characterized by widespread skin lesions, which manifest as red, itchy, swollen, cracked, weeping lesions with crusting/scaling, intractable pruritus and enhanced susceptibility to bacterial and viral skin infections.

As per DelveInsight estimates, the higher prevalent population of Uncontrolled Atopic Dermatitis is observed in the United States as compared to EU5 countries and Japan. The prevalent population of Uncontrolled Atopic Dermatitis in the U.S. was found to be approximately 7 million in 2016. The total number of prevalent population of Atopic Dermatitis was estimated at around 40 million and a total number of prevalent population of Pruritus in Atopic Dermatitis was estimated at 20.5 million in 2016 in 7MM.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Galderma Pharma
2. LEO Pharma
3. Roivant Sciences
4. Dermira
5. Otsuka Pharmaceutical
And many others

Drugs covered

1. Nemolizumab
2. Tralokinumab
And many others

Report Scope
The report covers a descriptive overview of the Atopic Dermatitis (AD), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Atopic Dermatitis disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis is provided, along with an assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Atopic Dermatitis market is included in the report, covering drug outreach in 7 MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atopic Dermatitis market